Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a Quadrivalent Hemagglutinin Nanoparticle Influenza and SARS-CoV-2 rS Nanoparticle Combination Vaccine With Matrix M1 Adjuvant in Healthy Participants ≥ 50 to ≤ 70 Years of Age

Next Previous
Trial Profile

A Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a Quadrivalent Hemagglutinin Nanoparticle Influenza and SARS-CoV-2 rS Nanoparticle Combination Vaccine With Matrix M1 Adjuvant in Healthy Participants ≥ 50 to ≤ 70 Years of Age

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NanoFlu/NVX CoV 2373 combination vaccine-Novavax (Primary) ; NVX CoV 2373 (Primary) ; Matrix-M1 Adjuvant
  • Indications COVID 2019 infections; Influenza virus infections
  • Focus Adverse reactions; Registrational
  • Sponsors Novavax

    • Most Recent Events

    • 23 Oct 2022 Preliminary safety, reactogenicity and immunogenicity results of COVID influenza combination vaccine in seropositive participants, presented at the IDWeek 2022.
    • 20 Oct 2022 According to a Novavax media release, new data from the trial will be presented at IDWeek 2022.
    • 13 Oct 2022 According to a Novavax media release, results from this trial were presented at the World Vaccine Congress (WVC) Europe 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top